
Myelodysplastic syndrome Program in Pharmaceutical Benefits Scheme (PBS) 012-18051125

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised azacitidine,
decitabine+cedazuridine and lenalidomide for patients with
myelodysplastic syndrome (MDS).

Myelodysplastic syndrome and listing dates

Myelodysplastic syndromes (MDS) are a group of disorders caused by
poorly formed or dysfunctional blood cells.

Listing dates are:

-   azacitidine – 1 February 2011
-   lenalidomide – 1 October 2013
-   decitabine+cedazuridine – 1 October 2022

For more information, see Written Authority Required for Drugs.

Enquiries

-   Transfer enquiries about prescription arrangements for azacitidine
    and lenalidomide to the PBS Complex Drugs Programs team and choose
    the option relevant to the condition treated
-   Transfer enquiries about prescription arrangements for
    decitabine+cedazuridine to PBS authority approvals

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Manage work items in PaNDA

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
